Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Pegvisomant for the treatment of acromegaly—translation of clinical trials into clinical practice

Nature Clinical Practice Endocrinology & Metabolism volume 3, pages 514–515 (2007)Cite this article

boxed-textSchreiber I et al. (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156: 75–82

The GPOS demonstrates that clinicians should be more aggressive in their use of pegvisomant dose-titration protocols in order to normalize serum IGF-I levels; in addition, serial safety monitoring should be routinely performed

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Trainer PJ et al. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171–1177

    Article  CAS  Google Scholar 

  2. van der Lely AJ et al. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358: 1754–1759

    Article  CAS  Google Scholar 

  3. Melmed S et al. (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153: 737–740

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA lkatznelson@stanford.edu

Authors and Affiliations

  1. L Katznelson is an Associate Professor of Neurosurgery and Medicine at Stanford University School of Medicine, Stanford, CA, USA.,

    Laurence Katznelson

Authors
  1. Laurence Katznelson
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Dr Katznelson has received research support from Ipsen and Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Katznelson, L. Pegvisomant for the treatment of acromegaly—translation of clinical trials into clinical practice. Nat Rev Endocrinol 3, 514–515 (2007). https://doi.org/10.1038/ncpendmet0533

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0533

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing